Abstract submissions for ProCan Conference are open!

ProCan Conference, ‘Advancing Multi-Omics into the Clinic’ is taking place in Sydney, Australia on November 18-19, 2024. .

Through this two-day meeting, internationally renowned experts in proteomics, genomics, cancer management, biomarker, and drug discovery will share their progress towards addressing the challenges and opportunities of multi-omics data integration in cancer management, with a special focus on the role of proteomics in advancing biomarker development and drug discovery.

Register here.

Important Dates

Registration opening – May 9th,
Call for abstracts – May 9th,
Abstract submission deadline – September 9th,
Early bird registration closing – September 16th,
Conference commences – November 18th.

Abstract Guidelines

Word Count: Maximum word count of 250 words (excluding title and affiliations).
Structure: Include sections on Background, Objective, Methods, Results, and Conclusions.
Font and Formatting: Arial 12 points.
Language: English.
Type: Indicate if the abstract being submitted would be oral only, poster only or either.
Keywords: Please provide a list of keywords that best represent the content of the abstract to help indexing and searching the abstract in the database. List up to 6 keywords further from any already in the title.
Affiliations and Authors’ Information: Include authors’ names, affiliations (e.g., institutions, universities), and contact information.
Content Guidelines: Abstracts should provide a clear and concise summary of the work being presented, including the purpose, methods, key findings, and conclusions.
Registration Requirement: Submitters need to be registered for the conference before submitting their abstracts.
Notification of Acceptance: The Conference Committee will review all abstracts and inform of the decision.
Abstracts Submission Deadline: 9th of September 2024.

You may submit an abstract to be a poster, or oral presenter, or both.

Please note, all submitters must register to attend the Conference. If you do not register to attend the Conference, your abstract submission will be forfeited.

View the following document on how to submit an abstract.

Speakers

• Jennifer Van Eyk is an international leader in clinical proteomics, focuses on developing personalized biomarkers and individualized therapies via developing technical pipelines for large scale quantitative protein mass spectrometry. At Cedars-Sinai Medical Center she directs the Advanced Clinical BioSystems Research Institute with the motto, “from discovery to patient care”.
• Bing Zhang, Cancer Prevention and Research Institute of Texas (CPRIT) Scholar, McNair Medical Institute Scholar, and Professor of Molecular and Human Genetics at Baylor College of Medicine. Over the past decade, he has led an internationally recognized research program in computational cancer proteogenomics, focusing on integrating genomic and proteomic data to enhance understanding of cancer biology and improve diagnosis and treatment.
• David Thomas is the inaugural Director of the Centre for Molecular Oncology at the University of New South Wales, and Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research. He is also CEO of Omico, a not-for-profit company he established to lead a national precision medicine program for patients with rare and early onset cancers. As a clinician-scientist, his focus is on the application of genomic technologies to the understanding and management of cancer, particularly sarcoma.
• Bernhard Kuster, Full Professor of Proteomics at Technical University of Munich (TUM), Director of the Bavarian Biomolecular Mass Spectrometry Center, Fellow of the TUM Institute for Advanced Study, Principal Investigator of the German Cancer Center and a member of the German National Academy of Science Leopoldina. Bernhard’s research in the area of cancer focuses on understanding how therapeutic drugs impact cellular signalling pathways that are active in individual patients and how this information can be used for therapy recommendations in molecular tumor boards.
• Ruedi Aebersold is a renowned scientist, obtained his Ph.D. in Molecular Biology from the University of Basel. As a Professor at ETH Zurich and the University of Zurich, he’s a leading figure in proteomics and systems biology. His achievements, including the Körber European Science Prize, underscore his profound impact. Co-founder of the Institute of Molecular Systems Biology.
• Christopher Whelan is a neuroscience and multi-omics researcher from Dublin, Ireland. He formed the ENIGMA-Epilepsy neuroimaging consortium, combining brain scans from 20 laboratories worldwide. In 2016, Chris moved to industry R&D, assuming roles of increasing responsibilities at Pfizer, Biogen, and most recently, Janssen in Cambridge, Massachusetts. Chris co-founded and chairs the Pharma Proteomics Project – a consortium of 13 biopharmaceutical companies generating proteomic data at population scale, including 55,000 blood plasma samples in the UK Biobank.

For more information view CMRI, ProCan, and ACRF.